Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Kg

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Dr. Karl Thomae Gmbh

Karl Thomae Gmbh

Horst Dollinger

Birgit Jung

Gerd Schnorrenberg

Georg Speck

Franz Esser

Domnic Martyres

Hans Briem

Peter Nickolaus

Ralf Anderskewitz

Christoph Hoenke

Pascale Pouzet

Rolf Goeggel

Erich Burger

Juergen Mack

Kurt Schromm

Matthias Hoffmann

Dennis Fiegen

Riccardo Giovannini

Thierry Bouyssou

Franz Birke

Klaus Klinder

Marc Grundl

Thomas Fox

Peter Seither

Jan Magnus Kriegl

Georg Rast

Klaus Rudolf

Henri Doods

Wolfgang Eberlein

Wolfhard Engel

Wolfgang Wienen

Joerg Kley

Herbert Nar

Gerhard Mihm

Michael Entzeroth

Rainer Walter

Hans Michael Jennewein

Claudia Heine

Bernd Disse

Sven Luettke

Klaus-Dieter Willim

Jurgen Krause

Heike Andrea Wieland

Georg Dahmann

Andreas Schnapp

Christian Gnamm

Jasna Klicic

Christine Braun

David James Lamb

Pascale Arielle Jane-Josee Pouzet

Gerd Schorrenberg

Claudia Thies

Kai Hasselbach

Brigit Jung

Jurgen Mack

Dihydrothienopyrimidinesulphoxides of formula 1 wherein X is SO or SO, Ris H or C-alkyl, Ris H or an organic group as disclosed herein, and Ris an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl, and the pharmacologically acceptable salts thereof, as well as pharmaceutical compositions which contain these compounds. These dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system, or cancers.

Heterocycle-substituted piperazino-dihydrothienopyrimidines

The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula 1 whereinR, R, R, Rand Rare defined as in claimand pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.

Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments

Object of the present invention are novel substituted compounds of the formula 1, wherein A, R, R, Rand Rare defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Substituted piperidines as CCR3 antagonists

The invention relates to new pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system and cancers. This invention also relates to pharmaceutical compositions containing these compounds.

Substituted pteridines

Piperidinodihydrothienopyrimidines of formula 1 wherein X is SO or SO(preferably SO), and R, R, R, and Rmay have the meanings given in the disclosure and claims, pharmacologically acceptable salts thereof, and pharmaceutical compositions containing these compounds. These piperidinodihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system, or cancers.

Substituted piperazino-dihydrothienopyrimidines

Therapeutic methods employing substituted piperidines which are CCR3 antagonists

Compounds of formula 1 and hetero derivatives thereof and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

Compounds for the treatment of inflammatory diseases

The invention relates to new pteridines which are suitable for the treatment of

Substituted pteridines for the treatment of inflammatory diseases

The invention relates to new pteridine compounds of formula 1  wherein R, R, Rand Rhave the meanings given herein, which are useful for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system, or cancers. The invention further relates to pharmaceutical compositions which contain these compounds.

Described are new pteridine compounds of the formula 1, where the variables are as described herein. The compounds are useful for the treatment of: respiratory or gastrointestinal complaints or diseases; inflammatory diseases of the joints, skin or eyes; diseases of the peripheral or central nervous system; and cancers. Also described are pharmaceutical compositions which contain these compounds.

Growing community of inventors

Schemmerhofen, Germany

Horst Dollinger